trending Market Intelligence /marketintelligence/en/news-insights/trending/LMHRTE8XFUjEcz25eg6yxg2 content esgSubNav
In This List

Bicycle Therapeutics secures £40M in financing

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


Bicycle Therapeutics secures £40M in financing

Bicycle Therapeutics secured £40 million in a series B financing led by Vertex Ventures HC.

Other participants include new investors Cambridge Innovation Capital and Longwood Fund, as well as existing investors Novartis Venture Fund, SROne, SVLS and Atlas Venture.

The company said it will use proceeds to further develop its lead molecule BT1718, which targets malignant tumors.

Additionally, the financing will help advance Bicycle Therapeutics' preclinical programs, which include toxin drug conjugates and immune modulators.